VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

4.92USD
12:16pm EDT
Price Change (% chg)

$0.11 (+2.29%)
Prev Close
$4.81
Open
$4.85
Day's High
$4.95
Day's Low
$4.81
Volume
152,877
Avg. Vol
548,800
52-wk High
$15.13
52-wk Low
$4.54

VVUS.OQ

Chart for VVUS.OQ

About

VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as... (more)

Overall

Beta: 1.35
Market Cap (Mil.): $496.94
Shares Outstanding (Mil.): 103.31
Dividend: --
Yield (%): --

Financials

  VVUS.OQ Industry Sector
P/E (TTM): -- 36.00 36.40
EPS (TTM): -1.35 -- --
ROI: -50.04 19.00 18.27
ROE: -86.26 19.78 19.15
Search Stocks

Deals of the day- Mergers and acquisitions

(Adds Stryker, Vivus, Transcontinental, Orange, St. Jude Medical; Updates Weir, Valeant, General Electric)

28 May 2014

Top Vivus shareholder plans to buy company in $640 million deal

- Vivus Inc's biggest shareholder said it was planning to buy the obesity drug maker in a deal valued at $640 million, the latest shareholder attempt to revive a company that has struggled to boost sales of its key drug.

28 May 2014

UPDATE 2-Top Vivus shareholder plans to buy company in $640 mln deal

May 28 - Vivus Inc's biggest shareholder said it was planning to buy the obesity drug maker in a deal valued at $640 million, the latest shareholder attempt to revive a company that has struggled to boost sales of its key drug.

28 May 2014

US STOCKS-Wall St dips; S&P holds above 1,900 after hitting new peak

* Indexes off: Dow 0.2 pct, S&P 0.1 pct, Nasdaq 0.2 pct (Updates to morning trading, adds comment, Vivus)

28 May 2014

Vivus shareholder Aspen plans to buy company for $640 mln

May 28 - Aspen Investment Fund, a shareholder of obesity drug maker Vivus Inc, said it was planning to offer to buy the company for $640 million.

28 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks